Major Male Pelvic Procedures with CC/MCC DRG Reimbursement

DRG 707 includes major male pelvic procedures with a Complication or Comorbidity or Major Complication or Comorbidity and encompasses extensive urologic resections and complex pelvic operations in hospitalized male patients. Proper assignment matters for inpatient reimbursement because the presence of Complication or Comorbidity or Major Complication or Comorbidity increases clinical severity and typically results in higher Medicare payment relative to lower-severity procedure groups.

DRG 707 Overview

DRG 707 covers major male pelvic procedures performed on hospitalized adult male patients when a Complication or Comorbidity or Major Complication or Comorbidity is present, typically including extensive urologic resections, reconstructive pelvic surgery, and complex prostate operations. This Diagnosis-Related Group groups cases with higher clinical severity and resource use, which affects inpatient payment under Medicare’s prospective payment system. Cases assigned to this Diagnosis-Related Group generally generate higher reimbursement than lower-severity pelvic procedure groups due to added complications or comorbid conditions. Understanding the clinical scope of DRG 707 is important for accurate coding and payment classification.

Perioperative interventions to reduce surgical complications in major male pelvic procedures: randomized or pragmatic trials testing enhanced recovery protocols, antibiotic/antithrombotic timing strategies, or optimized fluid and pain management in men undergoing radical prostatectomy, cystectomy, or pelvic lymphadenectomy. These studies enroll patients scheduled for major male pelvic surgery and measure short-term outcomes such as postoperative infection, bleeding, return of bowel function, length of stay, and 30-day readmission. Results inform clinicians and hospital payers about interventions that safely reduce morbidity and resource use in a high-cost inpatient DRG.
Comparative effectiveness studies of surgical technique or extent of resection in male pelvic oncologic operations: prospective cohort or randomized studies comparing approaches (for example radical versus organ-sparing procedures, open versus minimally invasive/robotic approaches, or variations in lymph node dissection templates) in men with prostate, bladder, or pelvic urologic cancers. These trials target heterogeneous surgical candidates stratified by tumor stage, comorbidity, and baseline urinary/sexual function, assessing disease control, functional outcomes, complication rates, and downstream utilization over months to years. Findings help providers and payers balance long-term oncologic benefit and quality-of-life outcomes against upfront inpatient costs captured under this DRG.
Post-discharge recovery and health services research focusing on readmission reduction and rehabilitation needs after major male pelvic surgery: observational and interventional studies evaluating care-transition models, home-based rehabilitation, telemonitoring, or targeted outpatient support for men discharged after pelvic procedures. These studies follow patients with varying frailty and comorbidity profiles to identify predictors of readmission, prolonged dependency, or durable functional impairment and to test interventions that reduce post-discharge complications and emergency utilization. Evidence from this research informs discharge planning, case management strategies, and payer policies to reduce costly readmissions and improve value for patients assigned to this DRG.

Perioperative interventions to reduce surgical complications in major male pelvic procedures: randomized or pragmatic trials testing enhanced recovery protocols, antibiotic/antithrombotic timing strategies, or optimized fluid and pain management in men undergoing radical prostatectomy, cystectomy, or pelvic lymphadenectomy. These studies enroll patients scheduled for major male pelvic surgery and measure short-term outcomes such as postoperative infection, bleeding, return of bowel function, length of stay, and 30-day readmission. Results inform clinicians and hospital payers about interventions that safely reduce morbidity and resource use in a high-cost inpatient DRG.
Comparative effectiveness studies of surgical technique or extent of resection in male pelvic oncologic operations: prospective cohort or randomized studies comparing approaches (for example radical versus organ-sparing procedures, open versus minimally invasive/robotic approaches, or variations in lymph node dissection templates) in men with prostate, bladder, or pelvic urologic cancers. These trials target heterogeneous surgical candidates stratified by tumor stage, comorbidity, and baseline urinary/sexual function, assessing disease control, functional outcomes, complication rates, and downstream utilization over months to years. Findings help providers and payers balance long-term oncologic benefit and quality-of-life outcomes against upfront inpatient costs captured under this DRG.
Post-discharge recovery and health services research focusing on readmission reduction and rehabilitation needs after major male pelvic surgery: observational and interventional studies evaluating care-transition models, home-based rehabilitation, telemonitoring, or targeted outpatient support for men discharged after pelvic procedures. These studies follow patients with varying frailty and comorbidity profiles to identify predictors of readmission, prolonged dependency, or durable functional impairment and to test interventions that reduce post-discharge complications and emergency utilization. Evidence from this research informs discharge planning, case management strategies, and payer policies to reduce costly readmissions and improve value for patients assigned to this DRG.

OpenPayer

Summary & Overview

Major Male Pelvic Procedures with CC/MCC: Inpatient Reimbursement Overview

DRG 707 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes